News & Events

Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD

Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIA Therapeutic dose of 600 mg varoglutamstat given twice daily selected by […]

Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022

Data underscore the unique potential of Vivoryon’s N3pE-focused strategy in mono- and combination therapy settings in AD Combination treatment of aducanumab and varoglutamstat achieves additive effect […]

Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD

Parallel group, dose-finding part of the study completed DSMB recommends that the study should proceed with a maximum dose of 600 mg BID varoglutamstat or placebo […]

Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022

All proposed resolutions approved All existing members re-appointed Board strengthened and diversified HALLE (SAALE) / MUNICH, GERMANY, June 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: […]

Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress

HALLE (SAALE) / MUNICH, GERMANY, June 15, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]

Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022

Halle (Saale) / Munich, Germany, June 08, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]

Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022

Halle (Saale) / Munich, Germany, May 11, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon; or the Company), a clinical stage company focused on discovery and development of […]

Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress

Substantial progress in clinical development of QPCT/L inhibitor varoglutamstat, EU and U.S. clinical studies in AD on track FDA Fast Track designation for lead product candidate […]

Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022

Halle (Saale) / Munich, Germany, April 21, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]